On 10 October, a paper titled Multi-analyte proteomic analysis identifies blood-based neuroinflammation, cerebrovascular and synaptic biomarkers in preclinical Alzheimer’s disease was published in Molecular Neurodegeneration. The study, led by researchers from the University of Pittsburg, highlights the use of the NULISAseq CNS disease panel, a novel proteomic method capable of simultaneously measuring 116 analytes related to neurodegenerative diseases, including core Alzheimer's disease (AD) biomarkers like tau and amyloid-beta, as well as non-core markers for processes such as neuroinflammation and cerebrovascular dysfunction. The research, involving 113 participants from southwestern Pennsylvania, identified blood-based biomarkers that could support earlier detection and monitoring of AD. The platform shows potential for broader use in research, aiding in the study of preclinical stages of the disease. The article is open access and can be read here:
https://molecularneurodegeneration.biomedcentral.com/articles/10.1186/s13024-024-00753-5